X4 Pharmaceuticals Completes Key Study on Mavorixafor’s Drug Interaction Potential

X4 Pharmaceuticals ((XFOR)) announced an update on their ongoing clinical study.

Study Overview: X4 Pharmaceuticals has completed a Phase I clinical study titled A Phase I, Randomized, Open-label, Drug-drug Interaction Study to Assess the Effect of Multiple Doses of a Moderate and a Strong CYP3A Inducer on the Pharmacokinetics and Safety of Mavorixafor in Healthy Male and Female Participants. The study aimed to evaluate the drug-drug interaction potential of mavorixafor when combined with CYP3A inducers, carbamazepine and efavirenz, in healthy individuals. This research is significant as it explores the safety and pharmacokinetics of mavorixafor, potentially impacting its therapeutic use and market positioning.

Intervention/Treatment: The study tested mavorixafor, an oral drug, in combination with carbamazepine and efavirenz, which are CYP3A inducers. The purpose was to assess how these combinations affect the body’s processing of mavorixafor, providing insights into its safety and efficacy profile.

Study Design: The study was interventional with a randomized, crossover model and no masking. Its primary purpose was basic science, focusing on understanding the pharmacokinetics of mavorixafor in the presence of other drugs.

Study Timeline: The study began on February 18, 2025, and was last updated on June 30, 2025. These dates are crucial as they mark the study’s progress and provide a timeline for data analysis and potential publication of results.

Market Implications: The completion of this study could influence X4 Pharmaceuticals’ stock performance by providing new data on mavorixafor’s safety and interaction profile. Positive results may enhance investor confidence and position the company favorably against competitors in the pharmaceutical industry.

The study is completed, and further details are available on the ClinicalTrials portal.